TherapeuticsMD, Inc. (NASDAQ:TXMD) has made a 38.57% comeback from a 12-month low price of $3.5. It was seen 5.9% higher, changing the price to $4.85, when the closing bell rang on Oct. 16, 2017. At recent session, the prices were hovering between $4.65 and $4.87. This company shares are 179.59% off its target price of $13.56 and the current market capitalization stands at $1.07B. The recent change has given its price a -16.32% deficit over SMA 50 and -41.53% deficit over its 52-week high. The stock witnessed -26.52% declines, -7.79% declines and 0% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found TXMD’s volatility during a week at 5.59% and during a month it has been found around 5.49%.TherapeuticsMD, Inc. (TXMD) Top Holders
Institutional investors currently hold around $716 million or 73.9% in TXMD stock. Look at its top three institutional owners. Fmr Llc owns $120.83 million in TherapeuticsMD, Inc., which represents roughly 11.29% of the company’s market cap and approximately 16.88% of the institutional ownership. Similar statistics are true for the second largest owner, Bank Of New York Mellon Corp, which owns 22,892,018 shares of the stock are valued at $104.85 million. The third largest holder is Price T Rowe Associates Inc /Md/, which currently holds $91.72 million worth of this stock and that ownership represents nearly 8.57% of its market capitalization.TherapeuticsMD, Inc. 13F Filings
At the end of June reporting period, 68 institutional holders increased their position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by some 13,026,593 shares, 59 decreased positions by 20,221,579 and 20 held positions by 123,088,629. That puts total institutional holdings at 156,336,801 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 598,616 shares while 27 institutional investors sold out their entire positions totaling 8,642,136 shares.
Multiple company employees have indulged in significant insider trading. TherapeuticsMD, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Thompson Tommy G has acquired 5,000 shares of TherapeuticsMD, Inc. (TXMD) in trading session dated Aug. 30, 2017. These shares are worth $29,950 and were traded at $5.99 each. The SEC filing shows that Collins Cooper C. performed a purchase of 16,000 shares. The Director added these shares by way of transaction on Mar. 11, 2016. The company’s shares were assimilated at $6.23 per share worth to an investment of some $99,680 on account of Collins Cooper C..
Director, Russell Angus C., purchased 13,500 common shares of TherapeuticsMD, Inc. (TXMD) in the open market. In a transaction dated Aug. 25, 2015, the shares were bought at an average price of $5.98, giving away a sum of $80,730. After this purchase, 48,500 common shares of TXMD are directly owned by the insider, with total stake valued at $235,225.
In the transaction dated Aug. 20, 2015, the great number of shares acquired came courtesy the Director; Thompson Tommy G added a total of 10,798 shares at an average price of $6.29, amounting to approximately $67,919. The insider now directly owns 663,055 shares worth $3,215,817.TherapeuticsMD, Inc. (TXMD) Analyst Guide
Several analysts have released their opinion on TherapeuticsMD, Inc. (NASDAQ:TXMD), with 7 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.25 average brokerage recommendation.